

Janet E Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9555892/publications.pdf>

Version: 2024-02-01

65
papers

5,569
citations

136950

32
h-index

128289

60
g-index

70
all docs

70
docs citations

70
times ranked

5542
citing authors

#	ARTICLE	IF	CITATIONS
1	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. <i>Lancet</i> , The, 2011, 377, 813-822.	13.7	1,748
2	Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2005, 97, 59-69.	6.3	522
3	Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid. <i>Journal of Clinical Oncology</i> , 2005, 23, 4925-4935.	1.6	493
4	Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. <i>Cancer</i> , 2008, 113, 193-201.	4.1	243
5	Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6336-6342.	7.0	171
6	Metastatic bone disease: Pathogenesis and therapeutic options. <i>Journal of Bone Oncology</i> , 2019, 15, 100205.	2.4	153
7	Skeletal complications and survival in renal cancer patients with bone metastases. <i>Bone</i> , 2011, 48, 160-166.	2.9	152
8	Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. <i>Clinical Cancer Research</i> , 2019, 25, 2769-2782.	7.0	120
9	The role of bisphosphonates in breast and prostate cancers.. <i>Endocrine-Related Cancer</i> , 2004, 11, 207-224.	3.1	109
10	Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. <i>Cancer Treatment Reviews</i> , 2008, 34, 629-639.	7.7	108
11	Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. <i>Endocrine-Related Cancer</i> , 2014, 21, 327-341.	3.1	89
12	Consensus on the utility of bone markers in the malignant bone disease setting. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 411-432.	4.4	84
13	Denosumab in patients with cancer—a surgical strike against the osteoclast. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 110-118.	27.6	81
14	Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. <i>JAMA Oncology</i> , 2016, 2, 493.	7.1	78
15	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4064-4075.	1.6	78
16	Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6348-6355.	7.0	76
17	CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	75
18	The role of biomarkers in the management of bone-homing malignancies. <i>Journal of Bone Oncology</i> , 2017, 9, 1-9.	2.4	71

#	ARTICLE	IF	CITATIONS
19	Skeletal metastasis in renal cell carcinoma: Current and future management options. <i>Cancer Treatment Reviews</i> , 2012, 38, 284-291.	7.7	69
20	Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid. <i>Clinical Cancer Research</i> , 2007, 13, 5406-5410.	7.0	68
21	Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 805-814.	2.5	62
22	Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 767-779.	2.5	62
23	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1556.	7.1	62
24	Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. <i>Supportive Care in Cancer</i> , 2016, 24, 1327-1337.	2.2	61
25	Cancer Treatment and Bone Health. <i>Calcified Tissue International</i> , 2018, 102, 251-264.	3.1	60
26	Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2010, 12, 685-696.	5.3	43
27	Osteonecrosis of the Jaw and Oral Health-Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04). <i>Journal of Clinical Oncology</i> , 2013, 31, 2685-2691.	1.6	41
28	The value of biomarkers in bone metastasis. <i>European Journal of Cancer Care</i> , 2017, 26, e12725.	1.5	39
29	Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. <i>Clinical Cancer Research</i> , 2016, 22, 5713-5721.	7.0	37
30	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. <i>Health Technology Assessment</i> , 2019, 23, 1-328.	2.8	35
31	The role of bisphosphonates in breast cancer: The present and future role of bisphosphonates in the management of patients with breast cancer. <i>Breast Cancer Research</i> , 2001, 4, 24-9.	5.0	34
32	Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. <i>Journal of Bone Oncology</i> , 2013, 2, 70-76.	2.4	34
33	Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. <i>Journal of Pathology</i> , 2019, 247, 381-391.	4.5	33
34	Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 871-879.	6.3	32
35	Complications of bone metastases from malignant melanoma. <i>Journal of Bone Oncology</i> , 2017, 8, 13-17.	2.4	29
36	Bone Health in Men with Prostate Cancer: Review Article. <i>Current Osteoporosis Reports</i> , 2019, 17, 527-537.	3.6	28

#	ARTICLE	IF	CITATIONS
37	Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. <i>Journal of Bone Oncology</i> , 2020, 25, 100311.	2.4	27
38	Effect of Chemotherapy on Skeletal Health in Male Survivors from Testicular Cancer and Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 6480-6486.	7.0	26
39	Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement. <i>European Urology Focus</i> , 2020, 6, 991-998.	3.1	23
40	Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. <i>Cancers</i> , 2020, 12, 2109.	3.7	23
41	Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 5300-5314.	0.9	22
42	A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS. <i>PLoS ONE</i> , 2018, 13, e0197606.	2.5	19
43	Metastatic Bone Disease. <i>American Journal of Cancer</i> , 2003, 2, 269-281.	0.4	17
44	Assessment of the effects of breast cancer on bone and the response to therapy. <i>Breast</i> , 2002, 11, 375-385.	2.2	16
45	OSTEOPOROSIS IN PATIENTS WITH PROSTATE CANCER ON LONG-TERM ANDROGEN DEPRIVATION THERAPY: AN INCREASING, BUT UNDER-RECOGNIZED PROBLEM. <i>BJU International</i> , 2010, 105, 1042-1043.	2.5	16
46	Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 589-601.	4.1	16
47	Setting Research Priorities in Partnership with Patients to Provide Patient-centred Urological Cancer Care. <i>European Urology</i> , 2019, 75, 891-893.	1.9	12
48	Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. <i>British Journal of Cancer</i> , 2022, 126, 419-429.	6.4	10
49	The development of a theory and evidence-based intervention to aid implementation of exercise into the prostate cancer care pathway with a focus on healthcare professional behaviour, the STAMINA trial. <i>BMC Health Services Research</i> , 2021, 21, 273.	2.2	8
50	Myeloma Bone Disease: The Osteoblast in the Spotlight. <i>Journal of Clinical Medicine</i> , 2021, 10, 3973.	2.4	7
51	Efficacy of bisphosphonates and other bone-targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 281-7.	0.3	7
52	Towards implementing exercise into the prostate cancer care pathway: development of a theory and evidence-based intervention to train community-based exercise professionals to support change in patient exercise behaviour (The STAMINA trial). <i>BMC Health Services Research</i> , 2021, 21, 264.	2.2	6
53	Biomarkers of bone turnover in oncology: applications in diagnosis and treatment. <i>Expert Opinion on Medical Diagnostics</i> , 2010, 4, 125-138.	1.6	5
54	Dedicator of Cytokines 4: A Potential Prognostic and Predictive Biomarker Within the Metastatic Spread of Breast Cancer to Bone. <i>Cancer Informatics</i> , 2019, 18, 117693511986684.	1.9	5

#	ARTICLE	IF	CITATIONS
55	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. <i>European Urology Focus</i> , 2020, 6, 999-1005.	3.1	5
56	Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems. <i>BMC Cancer</i> , 2018, 18, 667.	2.6	4
57	Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. <i>Journal of Bone Oncology</i> , 2021, 28, 100367.	2.4	4
58	Bone Metastases; Clinical Aspects. , 2019, , 310-319.		3
59	Embedding supervised exercise training for men on androgen deprivation therapy into standard prostate cancer care: a feasibility and acceptability study (the STAMINA trial). <i>Scientific Reports</i> , 2021, 11, 12470.	3.3	3
60	Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer. <i>Diagnostics</i> , 2021, 11, 1302.	2.6	3
61	Bone-Targeted Therapies in Prostate Cancer. , 2017, , 343-356.		1
62	Treatment Strategies in Metastatic Renal Cancer: Dose Titration in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 293-294.	1.9	1
63	Assessment of the Impact of Targeted Therapy on Metastatic Bone Disease in Renal Cancer. <i>European Urology</i> , 2014, 66, 510-511.	1.9	0
64	Identification of new therapeutic targets of bone cancers by proteomic strategies. , 2022, , 783-803.		0
65	Novel mediators of breast cancer bone metastasis—insights from studies of gene-regulation and the global proteome. <i>Annals of Translational Medicine</i> , 2018, 6, S71-S71.	1.7	0